46 results on '"Schechter, Meir"'
Search Results
2. Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease
3. Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease
4. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
5. Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
6. The effect of lifestyle intervention on cardiometabolic risk factors in mental health rehabilitation hostel residents at-risk: a cluster-randomized controlled 15-month trial
7. Normo-albuminuria- Is it normal? The association of urinary albumin within the "normoalbuminuric" range with adverse cardiovascular and mortality outcomes: a systematic review and meta-analysis. (Embase).
8. Normo-albuminuria- Is it normal? The association of urinary albumin within the "normoalbuminuric" range with adverse cardiovascular and mortality outcomes: a systematic review and meta-analysis. (PubMed).
9. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
10. Abstract 10006: The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
11. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
12. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
13. α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription
14. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty.
15. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty
16. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
17. Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data
18. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
19. A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
20. Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study
21. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: New Insights from CANVAS
22. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
23. 862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial
24. 867-P: Favorable Kidney Outcomes Are Associated with Empagliflozin vs. DPP4i in Patients with Diabetes and Normal Kidney Function Real-World Evidence
25. Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
26. Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
27. Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach
28. Additional file 1 of Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
29. Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains
30. An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinson’s Disease
31. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
32. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
33. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
34. Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood
35. Coping with Fear of Hypoglycemia Using a Smartphone Application Combining Biofeedback and Virtual Reality
36. Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
37. α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate
38. Additional file 2 of A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
39. Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis.
40. α-Synuclein Translocates to the Nucleus to Activate Retinoic Acid-Dependent Gene Transcription
41. α-Synuclein facilitates endocytosis by elevating the steadystate levels of phosphatidylinositol 4,5-bisphosphate.
42. Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson’s Disease
43. Additional file 1 of A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
44. Additional file 1 of A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease
45. Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
46. [IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.